Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BAK · NYSE · United States · Industrial Organic Chemicals
In shortBRASKEM SA is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1.4% | 12/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -14.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -1.2% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.31× | 43/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 12.52× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -0.16× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.00 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -1.7% | 13/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 40.7% | 0/100 |
| Operating margin volatility | 11.6% | 4/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -9.8% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
BRL millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 58,543 | 105,625 | 96,519 | 70,569 | 77,411 |
| Cost of revenue | 47,331 | 73,568 | 85,161 | 67,548 | 71,414 |
| Gross profit | 11,212 | 32,057 | 11,358 | 3,021 | 5,997 |
| Research & development | 251 | 297 | 374 | 383 | 463 |
| Selling, general & admin | (4,077) | (4,883) | (5,285) | – | – |
| Operating income | (72) | 26,044 | 4,272 | (2,792) | (1,079) |
| Interest expense | 4,913 | 4,903 | 5,066 | 5,589 | 6,853 |
| Pre-tax income | (9,684) | 17,961 | 47 | (6,192) | (17,733) |
| Income tax | (2,668) | 3,999 | 868 | (1,302) | (5,681) |
| Net income | (6,692) | 13,985 | (336) | (4,579) | (11,320) |
| Diluted EPS | −BRL8.41 | BRL17.57 | – | – | – |
| Diluted shares (millions) | 796 | – | – | – | – |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.00 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 31, 2025